載入中
NextCure, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative immunotherapies. Its core mission is to combat cancer and various other immune-related conditions by reactivating normal immune system function. The company's leading investigational compound, NC318, is currently in Phase II clinical trials, focusing on the treatment of advanced or metastatic solid tumors. Additionally, NextCure is progressing NC410 through Phase I studies; this novel immunomedicine is engineered to counteract immune suppression mediated by Leukocyte-Associated Immunoglobulin-like Receptor 1 (LAIR-1). Another asset, NC762, is an immunotherapeutic designed to target the human B7 homolog 4 protein (B7-H4). Furthermore, NC525, a distinct LAIR-1 antibody, is undergoing preclinical assessment for its potential efficacy against acute myeloid leukemia, specifically targeting blast cells and leukemic stem cells. Beyond these specific pipeline candidates, NextCure's broader research and development efforts encompass the preclinical evaluation of other promising immunomodulatory antibodies and molecules. The company operates under a licensing agreement with Yale University. NextCure, Inc. was established in 2015 and maintains its corporate headquarters in Beltsville, Maryland.
前收盤價
US$7.18
+US$0.40 · +5.90%
盤中時間採用ET。市場資料可能有所延遲。
NextCure, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative immunotherapies. Its core mission is to combat cancer and various other immune-related conditions by reactivating normal immune system function. The company's leading investigational compound, NC318, is currently in Phase II clinical trials, focusing on the treatment of advanced or metastatic solid tumors. Additionally, NextCure is progressing NC410 through Phase I studies; this novel immunomedicine is engineered to counteract immune suppression mediated by Leukocyte-Associated Immunoglobulin-like Receptor 1 (LAIR-1). Another asset, NC762, is an immunotherapeutic designed to target the human B7 homolog 4 protein (B7-H4). Furthermore, NC525, a distinct LAIR-1 antibody, is undergoing preclinical assessment for its potential efficacy against acute myeloid leukemia, specifically targeting blast cells and leukemic stem cells. Beyond these specific pipeline candidates, NextCure's broader research and development efforts encompass the preclinical evaluation of other promising immunomodulatory antibodies and molecules. The company operates under a licensing agreement with Yale University. NextCure, Inc. was established in 2015 and maintains its corporate headquarters in Beltsville, Maryland.
日內區間
目前US$7.18
52週區間
目前US$7.18
盤中時間採用ET。市場資料可能有所延遲。
GoAI 評分
賣出
估值
45
合理估值
情緒
45
多空交錯
風險
75
高風險
動能
20
強勢下行
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
NextCure, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative immunotherapies. Its core mission is to combat cancer and various other immune-related conditions by reactivating normal immune system function. The company's leading investigational compound, NC318, is currently in Phase II clinical trials, focusing on the treatment of advanced or metastatic solid tumors. Additionally, NextCure is progressing NC410 through Phase I studies; this novel immunomedicine is engineered to counteract immune suppression mediated by Leukocyte-Associated Immunoglobulin-like Receptor 1 (LAIR-1). Another asset, NC762, is an immunotherapeutic designed to target the human B7 homolog 4 protein (B7-H4). Furthermore, NC525, a distinct LAIR-1 antibody, is undergoing preclinical assessment for its potential efficacy against acute myeloid leukemia, specifically targeting blast cells and leukemic stem cells. Beyond these specific pipeline candidates, NextCure's broader research and development efforts encompass the preclinical evaluation of other promising immunomodulatory antibodies and molecules. The company operates under a licensing agreement with Yale University. NextCure, Inc. was established in 2015 and maintains its corporate headquarters in Beltsville, Maryland.
日內區間
目前US$7.18
52週區間
目前US$7.18
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 銷貨成本 | 218.5萬 USD | — | — | — | — |
| 毛利 | −218.5萬 USD | — | — | — | — |
| 研究與開發 | 4492.3萬 USD | 4148.8萬 USD | 4793.1萬 USD | 5419.9萬 USD | 5019.2萬 USD |
| 銷售、一般及管理費用 | 1269.3萬 USD | 1571.8萬 USD | 1970.6萬 USD | 2171萬 USD | 2057.3萬 USD |
| 營業費用 | 5543.1萬 USD | 5974.8萬 USD | 6763.7萬 USD | 7590.9萬 USD | 7076.5萬 USD |
| 利息收入 | — | — | — | 116.7萬 USD | 1319 USD |
| 利息支出 | — | — | — | — | 7.7萬 USD |
| 折舊和攤銷 | 218.5萬 USD | 286.5萬 USD | 368.4萬 USD | 412.4萬 USD | 417.7萬 USD |
| 營業利益 | −5761.6萬 USD | −5974.8萬 USD | −6763.7萬 USD | −7590.9萬 USD | −7076.5萬 USD |
| 淨利 | −5584.4萬 USD | −5565.4萬 USD | −6272.3萬 USD | −7473.3萬 USD | −6938.9萬 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI78.77萬0.00%2.3兆 USD0.03%US$381.94+0.63%
Vanguard Extended Market ETFVXF21.45萬0.00%954億 USD0.05%US$235+0.80%
iShares Micro-Cap ETFIWC7.69萬0.01%13.17億 USD0.60%US$183+0.11%
U.S. Micro Cap Portfolio ETFDFMC1.84萬0.00%75.58億 USD0.43%US$57.813+0.20%
Dimensional - US Core Equity 2 ETFDFAC400.020.00%885.96億 USD0.21%US$45.33+0.49%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCU.S. Micro Cap Portfolio ETFDFMCDimensional - US Core Equity 2 ETFDFACAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
